What is the significance of REGN727 targeting PCSK9?

REGN727 targets PCSK9, a protein that plays a critical role in regulating LDL cholesterol levels. Inhibiting PCSK9 is a promising therapeutic strategy for lowering 'bad' cholesterol, potentially offering a new and effective treatment option for patients with cardiovascular disease, especially those who do not respond well to statins.

What are the potential applications for REGN475 targeting NGF?

REGN475 targets nerve growth factor (NGF), a protein involved in the development and survival of nerve cells, as well as pain signaling. Antibodies targeting NGF have shown promise in treating various chronic pain conditions, osteoarthritis pain, and potentially other inflammatory disorders where NGF plays a significant role.

Are these clinical trial results final, or preliminary?

The results announced are preliminary. This means that while they show encouraging early signs, they are subject to further analysis and confirmation through ongoing and future clinical trials. Investors should anticipate additional data releases as the trials progress.

Where can I find more detailed information about these clinical trial results?

The press release dated May 12, 2010, which contains the details of these preliminary clinical trial results, is filed as Exhibit 99.1 to this Form 8-K. This document can be accessed through the SEC's EDGAR database or Regeneron's investor relations website.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on May 13, 2010, to announce important preliminary clinical trial results for two key antibody product candidates, REGN727 and REGN475. REGN727 is a fully human antibody designed to target PCSK9, a protein implicated in cholesterol regulation, suggesting potential for significant impact in cardiovascular disease treatment. REGN475, also a fully human antibody, targets NGF, indicating its potential application in areas of pain and inflammation management. These preliminary results are a critical development for Regeneron, as they represent progress in advancing its pipeline of antibody-based therapeutics. Investors will be closely watching the continued development and further trial data for these candidates, which could be significant drivers of future revenue and company valuation. The company has provided a press release detailing these findings, which is attached as an exhibit to this filing.

Key Highlights

1Regeneron announced preliminary clinical trial results for two antibody product candidates: REGN727 and REGN475.
2REGN727 is a fully human antibody targeting PCSK9, a key protein in cholesterol metabolism.
3REGN475 is a fully human antibody targeting nerve growth factor (NGF).
4The press release detailing these preliminary results is filed as Exhibit 99.1 to the 8-K.
5These results indicate progress in Regeneron's antibody development pipeline.
6The announcement is expected to be of significant interest to investors focused on cardiovascular and pain/inflammation therapeutics.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (May 13, 2010)

Summary

Key Highlights

Frequently Asked Questions